SecBot SecBot
8-K ·Filed Apr 30, 2026

BAX

BAXTER INTERNATIONAL INC
MIXED
Impact 5/10
Horizonweeks Processed6mo ago SEC0001628280-26-028582
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The EPS beat provides short-term relief, but the underlying organic revenue decline and reiterated guidance (flat growth, $1.85-$2.05 EPS) cap upside. Watch for resolution of the Novum IQ pump hold and tariff impact in Q2 commentary. The stock may trade range-bound until organic growth inflects positively.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$17.58
T+0 close · Apr 30, 2026 · via day close
Latest settled
+32.76%
T+60 · $23.34
Vs SPY
+29.66%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 30 $17.58entry
  2. T+1 · 7mo ago −2.10%α −2.32% · $17.21
  3. T+5 · 6mo ago −3.41%α −5.14% · $16.98
  4. T+20 · 6mo ago +9.50%α +4.53% · $19.25
  5. T+60 · 4mo ago +32.76%α +29.66% · $23.34
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Baxter reported Q1 2026 adjusted diluted EPS of $0.36, beating the $0.31 consensus by 16.1%, on revenue of $2.70B vs. $2.62B consensus (+3.1% beat). However, organic sales declined 1% YoY, adjusted EPS fell 35% YoY, and the company merely reiterated its full-year 2026 outlook of flat organic growth and adjusted EPS of $1.85-$2.05. The combination of a headline beat with deteriorating underlying trends (declining organic revenue, tariff headwinds, ongoing Novum IQ pump hold) makes this a mixed filing.

Key Financial Metrics

EPS
$0.36
est $0.31 · +16.1%
Revenue
$2.7B
est $2.6B · +3.1% · +2.9% YoY
Rating
beat
Guidance
flat to 1% reported growth; approximately flat organic growth
maintained
Free Cash Flow
$76.0M
Gross Margin
33%

Key Facts

  • Q1 2026 adjusted diluted EPS from continuing operations was $0.36, beating consensus of $0.31 by 16.1%
  • Q1 2026 revenue was $2.701B, beating consensus of $2.62B by 3.1%
  • Organic sales declined 1% YoY; U.S. organic sales fell 4%
  • Adjusted diluted EPS from continuing operations declined 35% YoY from $0.55
  • Full-year 2026 outlook reiterated: organic sales growth approximately flat, adjusted EPS $1.85-$2.05
  • GAAP diluted EPS from continuing operations was ($0.03), vs $0.13 in Q1 2025
  • Free cash flow from continuing operations was $76M, improving from ($221M) in Q1 2025
  • Quarterly dividend declared at $0.01 per share, unchanged
  • Novum IQ LVP shipment and installation hold continues to weigh on Infusion Therapies sales
  • Tariff costs and higher manufacturing costs impacted results in the quarter

Financial Impact

Adjusted EPS beat consensus by $0.05 (16.1%), but organic revenue declined 1% YoY and adjusted EPS fell 35% YoY

revenueepsorganic growthfree cash flow

Risk Factors

  • Novum IQ LVP shipment hold continues to pressure Infusion Therapies sales
  • Tariff costs and higher manufacturing costs are compressing margins
  • U.S. organic sales declined 4% YoY, signaling weak domestic demand
  • Adjusted EPS guidance of $1.85-$2.05 implies no acceleration from Q1 run-rate

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
23% bullish (22 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-028582
Document: bax-20260429.htm0001628280-26-028582
Document: 0001628280-26-028582-index-headers.html0001628280-26-028582
Document: 0001628280-26-028582-index.html0001628280-26-028582
Document: 0001628280-26-028582.txt0001628280-26-028582
8-K Data (Synthetic)0001628280-26-028582

Track record

15 reports on BAX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +9.15% at T+5 after the Oct 29, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $23.50 to $25.65 Now $25.54 +8.68% ▲ +9.15% +13.87% vs SPY
  2. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $24.92 to $25.49 Now $25.54 +2.49% ▲ +2.29% +4.28% vs SPY
  3. Oct 23, 202624d ago Institutional Cluster Neutral 2/10 Entry $25.30 to $23.00 Now $25.54 +0.95% ▼ −9.09% −8.53% vs SPY
  4. Aug 19, 202612w ago 8-K Neutral 3/10 Entry $26.64 to $26.50 Now $25.54 −4.13% ▼ −0.53% −0.14% vs SPY
  5. Aug 18, 202612w ago 8-K Mixed 5/10 Entry $26.64 to $26.50 Now $25.54 −4.13% ▼ −0.53% −0.14% vs SPY
  6. Aug 12, 202613w ago Institutional Cluster Bullish 4/10 Entry $26.95 to $26.64 Now $25.54 −5.23% ▼ −1.15% −0.71% vs SPY
  7. Aug 4, 202614w ago 8-K Neutral 4/10 Entry $28.35 to $27.61 Now $25.54 −9.91% ▼ −2.61% −2.51% vs SPY
  8. Jul 30, 202615w ago 8-K Bullish 7/10 Entry $26.75 to $27.01 Now $25.54 −4.52% ▲ +0.97% −2.65% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $20.49 to $19.39 Now $25.54 −24.65% ▲ +5.37% +5.80% vs SPY
  10. May 8, 202627w ago 8-K Neutral 2/10 Entry $17.53 to $17.79 Now $25.54 +45.69% ▲ +1.48% +1.57% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (9h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 30, 2026